SCHEMBL7561095

SCHEMBL7561095

CC(=NNC(=O)c1[nH]c2ccccc2c1C(C)C)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 3/20 0.50
CYP2C9 P11712 1/20 0.50
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA9 Q16790 2/20 0.46
MTOR P42345 1/20 0.46
RAB9A P51151 4/20 0.45
NPC1 O15118 2/20 0.45
AGTR1 P30556 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
NFKB1 P19838 1/20 0.43
CYP2C19 P33261 1/20 0.43
CASP3 P42574 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561090 1.00 MAPT (0.50) MAPTMEN1KMT2AALDH1A1CYP2C9
SCHEMBL7558851 0.89 NPC1 (0.50) MAPTMEN1KMT2AALDH1A1CYP2C9
SCHEMBL7529205 0.89 NPC1 (0.50) MAPTMEN1KMT2AALDH1A1CYP2C9
SCHEMBL7559004 0.86 ALDH1A1 (0.53) MAPTMEN1KMT2AALDH1A1MTOR
SCHEMBL7559001 0.86 ALDH1A1 (0.53) MAPTMEN1KMT2AALDH1A1MTOR
SCHEMBL7561358 0.85 MAPT (0.52) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL7561364 0.85 MAPT (0.52) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL7560469 0.80 MEN1 (0.59) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL7529919 0.80 MEN1 (0.59) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL7564275 0.79 RAB9A (0.60) MAPTMEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885MEN1 3165/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.